Announcement PDF ASX ANNOUNCEMENT Invion Limited ABN 76 094 730 417 Suite 2, Level 11, 385 Bourke Street, Melbourne VIC 3000, Australia P: +61 9692 7222 W: www.inviongroup.com RESULTS OF EXTRAORDINARY GENERAL MEETING MELBOURNE (AUSTRALIA) 29 May 2026: In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions put to shareholders of Invion Limited (ASX: IVX) (“Invion”) at its Extraordinary General Meeting held earlier today. This announcement was approved for release by the Company Secretary of Invion Limited. ____________________________________________ Investor and Media enquiries: Thian Chew (Chairman & CEO) T: +61 3 9692 7222 E: investor@inviongroup.com Brendon Lau (Investor & Media Relations) M: +61 409 341 613 E: brendon.lau@inviongroup.com About Invion Invion is a life-science company leading global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis, and infectious diseases. Invion holds the global exclusive license to the Photosoft technology for multiple cancer and non-cancer disease indications. Invion is listed on the ASX (ASX: IVX). Find out more at www.Inviongroup.com. About Next Generation Photodynamic Therapy (NGPDT) Invion is developing its platform PhotosoftTM technology as a novel Next Generation Photodynamic Therapy (NGPDT). NGPDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, NGPDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. NGPDT has also demonstrated potential in non-cancer disease areas including broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant “superbugs”, in addition to other indications. Invion Limited Extraordinary General Meeting Friday, 29 May 2026 Results of Meeting The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2. Resolution Details Instructions given to validly appointed proxies (as at proxy close) Number of votes cast on the poll (where applicable) Resolution Results Resolution Resolution Type For Against Proxy’s Discretion Abstain For Against Abstain* Carried / Not Carried 1. Approval of Proposed Transaction Ordinary 2,273,189 89.15% 198,049 7.77% 78,661 3.08% 6,500 2,351,850 92.23% 198,049 7.77% 6,500 Carried 2. Approval to issue Consideration Shares Ordinary 2,272,189 89.14% 198,049 7.77% 78,661 3.09% 7,500 2,350,850 92.23% 198,049 7.77% 7,500 Carried 3. Ratification of prior issue of Convertible Notes Ordinary 3,401,618 92.44% 199,599 5.42% 78,661 2.14% 8,500 3,480,279 94.58% 199,599 5.42% 8,500 Carried 4. Approval for issue of Convertible Notes Ordinary 3,405,841 92.52% 196,376 5.34% 78,661 2.14% 7,500 3,484,502 94.66% 196,376 5.34% 7,500 Carried 5. Approval for issue of Convertible Notes to Polar Ventures Limited Ordinary 2,271,560 89.16% 197,441 7.75% 78,661 3.09% 8,737 2,350,221 92.25% 197,441 7.75% 8,737 Carried 6a. Issue of Listed Options to the Lead Manager Ordinary 4,608,722 94.36% 196,599 4.03% 78,661 1.61% 18,682 4,687,383 95.97% 196,599 4.03% 18,682 Carried 6b. Issue of Broker Options to the Lead Manager Ordinary 4,603,793 94.24% 202,528 4.15% 78,661 1.61% 17,682 4,682,454 95.85% 202,528 4.15% 17,682 Carried 6c. Issue of Unlisted Options to the Lead Manager Ordinary 4,606,222 94.29% 200,099 4.10% 78,661 1.61% 17,682 4,684,883 95.90% 200,099 4.10% 17,682 Carried 7. Issue of unlisted Options to Mr Alex Berecz Ordinary 4,605,965 94.33% 198,305 4.06% 78,726 1.61% 19,668 4,684,691 95.94% 198,305 4.06% 19,668 Carried Resolution Details Instructions given to validly appointed proxies (as at proxy close) Number of votes cast on the poll (where applicable) Resolution Results Resolution Resolution Type For Against Proxy’s Discretion Abstain For Against Abstain* Carried / Not Carried 8. Approval of equity- based incentives for Mr Thian Chew Ordinary 2,067,560 81.47% 391,496 15.43% 78,661 3.10% 18,682 2,146,221 84.57% 391,496 15.43% 18,682 Carried 9a. Issue of Options to Mr Thian Chew Ordinary 2,270,870 89.17% 197,131 7.74% 78,661 3.09% 9,737 2,349,531 92.26% 197,131 7.74% 9,737 Carried 9b. Issue of Options to Mr Alan Yamashita Ordinary 4,466,032 94.16% 198,181 4.18% 78,661 1.66% 9,737 4,544,693 95.82% 198,181 4.18% 9,737 Carried 9c. Issue of Options to Mr Alistair Bennallack Ordinary 4,616,085 94.34% 195,681 4.00% 81,161 1.66% 9,737 4,697,246 96.00% 195,681 4.00% 9,737 Carried 10a. Issue of Incentive Options to Mr Thian Chew Ordinary 2,262,271 89.15% 196,775 7.75% 78,671 3.10% 18,682 2,340,942 92.25% 196,775 7.75% 18,682 Carried 10b. Issue of Incentive Options to Mr Alan Yamashita Ordinary 4,460,993 94.24% 194,275 4.10% 78,661 1.66% 18,682 4,539,654 95.90% 194,275 4.10% 18,682 Carried 10c. Issue of Incentive Options to Mr Alistair Bennallack Ordinary 4,611,046 94.41% 194,275 3.98% 78,661 1.61% 18,682 4,689,707 96.02% 194,275 3.98% 18,682 Carried *Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.